New Testicular Cancer Blood Test
|
UC San Diego Health is the first healthcare provider in the United States to offer a blood test measuring microRNA-371a-3P to guide treatment, detect early recurrence, and reduce CT scans in testicular cancer. “Being able to engage in translational research that radically impacts patient care,” according to Moores Member Aditya Bagrodia, MD, “is incredibly rewarding.” According to Moores Director Diane Simeone, MD, “This breakthrough [test] can save lives, while improving quality of life for cancer survivors.” Learn More»
|
Social Needs in Cancer Care
|
|
|
A study published in JCO Oncology Practice led by Moores Member Matthew (Mateo) P. Banegas, PhD, MPH, MS found that most community oncology practices screen for health-related social needs (79%) and financial distress (78%), with social workers leading referrals, which reveals opportunities to improve access to cancer care. Read more»
|
Sonia Ramamoorthy, MD Advances Physician Wellness
|
Moores Member Dr. Sonia Ramamoorthy, Chief of the Division of Colon and Rectal Surgery and Director of Physician Wellness at UC San Diego Health, leads initiatives to reduce burnout and support clinician well-being, which have earned national recognition from the AMA Joy in Medicine program. Learn More»
|
|
|
Science Funding and Immigration Drive Innovation
|
UC President James B. Milliken has articulated the essential role that both the UC system and immigration plays in driving economic growth. Indeed, according to Milliken, UC’s long-standing partnership with the U.S. federal government is what keeps the United States at the forefront of science, technology, and medicine worldwide. Learn More»
|
|
|
2025 Annual Moores Cancer Center Scientific Retreat |
Date: Thursday, November 6, 2025
Time: 7:30 a.m. to 5:00 p.m.
Place: Scripps Seaside Forum
|
This retreat will feature scientific presentations, a poster session, networking opportunities, and an afternoon keynote presentation. Registration for the scientific retreat is now closed. Learn More» | View Agenda»
|
|
|
The 2025 Translational Cancer Research Symposium |
Date: Friday, November 7, 2025
Time: 8:00 a.m. to 4:30 p.m.
Place: Health Sciences Auditorium (CISALUD)
|
The event will feature discussions on translational cancer research vis-a-vis the U.S.-Mexico border region. Registration is free! This is a wonderful way to strengthen binational dialogue around translational cancer research. Register Now»
|
|
|
FEATURED FUNDING OPPORTUNITIES |
View featured limited submission, federal, and non-federal grant and funding opportunities. |
American Cancer Society (ACS) Institutional Research Grant 2026 |
Moores Member Michael Bouvet, MD, Member of the Local Committee of the ACS Institutional Research Grant (ACS-IRG-24-1317140-51-IRG), is pleased to announce the availability of seed money to stimulate cancer research projects of high merit among junior investigators at UC San Diego.
|
Application Deadline: November 10, 2025
Apply Now»
|
Hanna and Mark Gleiberman Head & Neck Cancer Center 2025 Research Pilot Project Grant Opportunity
|
This grant will fund research projects to improve curative therapy and the quality of care for head and neck cancer patients and their families. Project proposals may target any aspect of head and neck cancer care or head and neck and/or voice disease etiology, diagnosis, and therapy.
|
Application Deadline: November 14, 2025
Apply Now»
|
ACTRI K12 Mentored Career Development Award
|
Equivalent to an NIH K23, K01, or K08, this award provides up to 3 years of support for early-career faculty members with $115,000/year toward salary, plus benefits, and $10,000/year in research and travel funds.
|
Application Deadline: November 21, 2025, 11:59 p.m. PST
Apply Now»
|
|
|
| Validation of a serum-based biomarker signature for detection of early-stage pancreatic ductal adenocarcinoma
|
Diane Simeone, MD (Cancer Biology and Signaling) and Jessica Everett, MS, CGC (Cancer Control)
|
|
|
| CarD-T: An automated pipeline for the nomination and analysis of potential human carcinogens |
Ludmil Alexandrov, PhD (Structural and Functional Genomics) and Parag Katira, PhD (Cancer Biology and Signaling)
|
|
|
|
Interactions of antibody drug conjugate anti-tubulin and topoisomerase I inhibitor payloads with radiotherapy to potentiate immunotherapy |
Robert Saddawi-Konefka, MD, PhD (Cancer Biology and Signaling [CBS]), Jyoti Mayadev, MD (Solid Tumor Therapeutics [STT]), Ramez Eskander, MD (STT), Silvio Gutkind, PhD (CBS), and Sunil Advani, MD (CBS)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
|
|
ALTE2131: Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
PI: Ramez Eskander, MD
NCT ID: NCT06513962
RYZ101-201: Phase Ib/II Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates and/or Chemotherapy (TRACY-1)
PI: Teresa Helsten, MD
NCT ID: NCT06590857
|
|
|
|
